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The Stromal Proteinase MMP3/Stromelysin-1
Promotes Mammary Carcinogenesis
MMP that can exert oncogenic effects. It can degrade
numerous ECM substrates, including collagens III, IV,
V, IX, X, and XI, laminins, elastin, entactin, fibronectin,
Mark D. Sternlicht,*§ Andre Lochter,²
Carolyn J. Sympson,² Bing Huey,³
Jean-Philippe Rougier,* Joe W. Gray,³
Dan Pinkel,³ Mina J. Bissell,² fibrin, fibrillins, fibulin, link protein, osteonectin, tenas-
cin, vitronectin, and ECM proteoglycans (reviewed inand Zena Werb*
*Department of Anatomy Sternlicht and Werb, 1999). Str1 can also release cell
surface molecules, including E-cadherin, L-selectin,University of California
San Francisco, California 94143-0452 heparin-binding EGF-like growth factor, and TNF-a; it
can activate other MMPs, including gelatinase B and²Life Sciences Division
Lawrence Berkeley National Laboratory the collagenases; and it can inactivate several serine
proteinase inhibitors (reviewed in Sternlicht and Werb,Berkeley, California 94720
³Cancer Genetics Program 1999). Importantly, Str1 was originally cloned (Matrisian
et al., 1985) and repeatedly recloned as a tumor-specificUniversity of California
San Francisco, California 94143-0808 gene (Muller et al., 1988; Ostrowski et al., 1988).
Str1 is expressed in stromal cells throughout mam-
mary development and is maximally expressed during
involution when ECM remodeling and alveolar regres-Summary
sion take place (Talhouk et al., 1992; Witty et al., 1995;
Lund et al., 1996). Although stromal cells synthesizeMatrix metalloproteinases (MMPs) are invariably upreg-
ulated in the stromal compartment of epithelial can- Str1 in vivo, the protein associates with the epithelium
(Talhouk et al., 1992; Lund et al., 1996). There are twocers and appear to promote invasion and metastasis.
Here we report that phenotypically normal mammary distinct responses to Str1 in mammary epithelium: prolif-
eration and branching in ductal cells, and apoptosis inepithelial cells with tetracycline-regulated expression
of MMP3/stromelysin-1 (Str1) form epithelial glandular differentiated secretory alveolar cells (Sympson et al.,
1994; Boudreau et al., 1995; Witty et al., 1995). Therestructures in vivo without Str1 but form invasive mes-
enchymal-like tumors with Str1. Once initiated, the are also parallels between development and neoplasia.
Expression of Str1 in the mammary epithelium of trans-tumors become independent of continued Str1 ex-
pression. Str1 also promotes spontaneous premalig- genic mice during development induces upregulation
of endogenous Str1 and other MMPs in surroundingnant changes and malignant conversion in mammary
glands of transgenic mice. These changes are blocked stromal fibroblasts and leads to fibrosis, neovasculari-
zation, and tenascin-C expression, all of which are hall-by coexpression of a TIMP1 transgene. The premalig-
nant and malignant lesions have stereotyped genomic marks of the reactive stroma of involution (Alexander et
al., 1996; Thomasset et al., 1998). Increased cell prolifer-changes unlike those seen in other murine mammary
cancer models. These data indicate that Str1 influ- ation, an altered stroma, angiogenesis, and tenascin-C
expression are also features of cancer progressionences tumor initiation and alters neoplastic risk.
(Borsi et al., 1992; Rùnnov-Jessen et al., 1996).
Here, we have examined how Str1 affects tumor pro-Introduction
gression using two genetic approaches: phenotypically
normal mammary epithelial cells that express Str1 in aExtracellular matrix (ECM)-degrading matrix metallopro-
tetracycline-regulated manner, and an Str1 transgeneteinases (MMPs) are universal features of carcinoma
targeted to mouse mammary glands by the mouse wheyprogression and are associated with tumor angiogen-
acidic protein (WAP) gene promoter. Our results indicateesis, invasion, and metastasis. MMPs not only foster
that not only can Str1 induce an altered stromal environ-invasion and spread by disrupting ECM barriers but also
ment, but as a product of such an environment, it canaffect cellular signaling by several routes (Werb, 1997;
promote the phenotypic conversion and malignantLukashev and Werb, 1998). Interestingly, most MMPs
transformation of mammary epithelial cells.are synthesized not by the genetically altered cancer
cells but by adjacent and intervening stromal cells
(Coussens and Werb, 1996). There is also a growing Results
awareness that stromal cells and the matrix microenvi-
ronment can influence initial tumor development (Ja- Str1 Promotes Epithelial-to-Mesenchymal
Transitions in Culturecoby et al., 1997; Howe et al., 1998; Hsieh et al., 1998;
Jacobs et al., 1999). Thus, given their stromal origin, Str1 has both ECM and cell surface targets (Sternlicht
and Werb, 1999). Thus, its biologic effects could ariseconsistent upregulation, and signaling capacity, stromal
MMPs may also contribute to the initial stages of cancer from its alteration of surrounding ECM or by its direct
action on the epithelial cells themselves. Therefore, wedevelopment.
MMP3/stromelysin-1 (Str1) is a candidate for a stromal treated an immortal but functionally normal mouse
mammary epithelial cell line (Scp2), which responds to
ECM signals but does not assemble its own ECM, with§ To whom correspondence should be addressed (e-mail: sternli@
itsa.ucsf.edu). recombinant Str1 (rStr1). Scp2 cells grow as an epithelial
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riphery (Figure 2A). Thus, induction of Str1 expression
triggered EMT and rendered the cells tumorigenic and
invasive in vivo.
When Tet was withheld from the drinking water for 12
days after injecting uninduced p2S10 cells and then
replaced for the remaining 4.3 weeks, tumor formation
was still seen, albeit at a lower rate than when Tet was
continuously absent (Figure 2B). This suggests that once
tumorigenicity is achieved, it would not be blocked by
repressing Str1 expression. To test this, we induced
Str1 expression in culture for 2 months in p2S10 and
Figure 1. Effect of Str1 on Morphology and Intermediate Filament p2S7 cells. When the preinduced cells were injected
Expression in Scp2 Cells into cleared fat pads, large tumors grew at all injected
Cells were maintained for 6 days in the (a) absence or (b) presence sites regardless of the presence or absence of Tet in
of activated recombinant Str1 (rStr1) and stained by indirect immu- the drinking water (Figure 2B). The tumors were highly
nofluorescence for cytokeratins (red) and vimentin (green). Nuclei
invasive and composed almost entirely of vimentin-posi-were counterstained with DAPI (blue). Scale bar, 50 mm.
tive spindle-shaped cells with fewer than 1% cytokera-
tin-positive cells (Figure 2Ae±h). Interestingly, several
tumors had small areas of differentiation to a cartilage-sheet with E-cadherin-rich adherens junctions and are
like phenotype (Figure 2Ae±h). Such changes, calledcytokeratin positive and vimentin negative. The rStr1
chondroid metaplasia, are also seen in human tumorsrapidly induced epithelial-to-mesenchymal transitions
with EMT and were first described three centuries ago(EMT), characterized by loss of cell±cell interactions,
(cited in Wargotz and Norris, 1989). Thus, once EMT isacquisition of a scattered morphology, downregulation
induced, converted cells no longer require Str1 trans-of epithelial cytokeratins, and upregulation of the mes-
gene stimulation to elicit an altered program of geneenchymal marker vimentin (Figure 1). These changes
expression and tumorigenesis.did not occur when the synthetic MMP inhibitor GM6001
The preinduced p2S10 cells also acquired the abilitywas also added (data not shown). This treatment of the
to form subcutaneous tumors with or without Tet in thecells in trans mimics the in vivo production of Str1 by
drinking water (data not shown). These tumors werefibroblasts acting on mammary epithelium.
about one-tenth the size of the orthotopic tumors but
had the same infiltrative spindle-cell morphology. NoStr1 Promotes EMT and Tumorigenicity In Vivo
other cells grew subcutaneously. Taken together, theseTo examine the effect of Str1 on Scp2 cells in vivo, we
data indicate that Str1 can trigger tumor progression inused Scp2 cells stably transfected with an autoactivat-
an immortal but functional mammary epithelial cell line.ing rat Str1 cDNA under the control of a tetracycline
(Tet)-repressible promoter (Lochter et al., 1997). These
transfected cells grow as epithelial sheets when grown Str1 Promotes the Development of Premalignant
and Malignant Mammary Lesionsin medium containing Tet, whereas induction of Str1
expression by Tet withdrawal results in EMT, cleavage in Transgenic Mice
To examine the long-term effect of Str1 on normal mam-and loss of E-cadherin, and acquisition of the ability
to form anchorage-independent colonies in agar and mary epithelial cells, we used WAP-Str1 transgenic
mice. We had previously observed precocious lobuloal-invade Matrigel (Lochter et al., 1997). For the present
study, we used two clones with regulated Str1 expres- veolar development in 3- to 10-week-old WAP-Str1
transgenic mice (Sympson et al., 1994) and an alteredsion (p2S7 and p2S10), a nonexpressing clone (p2S3),
and parental Scp2 cells. When Scp2 cells and Str1- reactive stroma in 2- to 4-month-old mice (Thomasset
et al., 1998). Here we found that 6- to 24-month-oldtransfected cells grown in the presence of Tet were
injected into surgically cleared (gland-free) mammary fat transgenic mice exhibited mammary abnormalities, pre-
malignant lesions, and malignancies (Figures 3 and 4). Ofpads of scid/scid mice, they grew and formed relatively
normal duct-like and pseudoglandular structures if the 163 mice from five independent transgenic lines (median
age 18 months), 77% had moderate or severe fibrosismice were given Tet in their drinking water (Figures 2Aa
and 2Ab). These structures had cytokeratin-8-positive, (collagen and fibroblast accumulation with adipocyte
loss), 64% had moderate or severe hyperplasia (epithe-vimentin-negative luminal cells but lacked smooth mus-
cle actin-positive myoepithelial cells that normally sur- lial cell accumulation), 53% had lymphocytic infiltrates,
20% had dysplasias (atypical proliferative lesions) orround luminal epithelium (Figures 2Ac and 2Ad). The duc-
tal structures did not branch, which is consistent with ductal carcinoma in situ, and 7.4% developed mammary
carcinomas.the lack of myoepithelial cells that produce epimorphin,
a morphogen required for branching (Hirai et al., 1998). The incidence of the various lesions was 1.2- to 1.9-
fold higher in parous mice than in virgin mice, and hyper-This growth pattern persisted for at least 13 weeks.
However, when Str1 expression was induced in vivo by plastic and fibrotic changes were generally more severe
in parous animals. Whereas increases in incidence andwithholding Tet from the drinking water, the p2S10 cells
formed small tumors in 5 of 18 injected sites by 6 weeks severity would be expected given the pregnancy-driven
nature of the WAP promoter, their modesty may reflect(Figure 2B). The tumors were composed largely of vi-
mentin-positive and cytokeratin-negative spindle-shaped the fact that the promoter is minimally active during
each estrus cycle, so that parity only slightly increases(mesenchymal-like) cells and were invasive at their pe-
Stromelysin-1 Promotes Mammary Carcinogenesis
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Figure 3. Incidence of Mammary Gland Pathologies in Str1 Trans-
genic Mice
The Str1-expressing transgenics include 100, 31, 16, 9, and 7 mice
from five independent transgenic lines, respectively. *, p , 0.00001
versus nontransgenic or nonexpressing transgenic controls (two-
tailed Fisher's exact test); ², p 5 0.002 and p 5 0.02 versus non-
transgenic and nonexpressing transgenic controls, respectively
(Fisher's exact test).
lifetime Str1 exposure. Indeed, even low transgene ex-
pression during puberty causes increased ductal branch-
ing and precocious lobuloalveolar development (Symp-
son et al., 1994), thus increasing the number of potential
target cells that are ªat riskº over an extended period
of time. Average tumor latency was 18.7 months, with
the first tumor appearing in a 6-month-old parous
mouse. The hyperplastic and fibrotic lesions tended to
be more severe in older animals, and the incidence of
hyperplasia increased from 46% at 6 months to 78% at
2 years of age. These data are consistent with a model
of multistage neoplastic progression induced by Str1
expression.
Mammary carcinomas were seen in mice from three
different founders (fewer than ten mice were studied in
the other two lines). Nine of the tumors were moderately
Figure 2. Effect of Str1 on Mammary Epithelial Growth In Vivo well-differentiated adenocarcinomas (Figure 5a±c), and
(A) Histologic appearance of p2S10 mammary epithelial cells grown three were undifferentiated tumors with evidence of
in cleared mammary fat pads. (a±d) Appearance of epithelial ductal EMT. Two of these were carcinosarcomas with cyto-
and gland-like structures (Ep) that form in the absence of Str1 ex- keratin-positive and vimentin-negative epithelial-like
pression as seen by (a) whole-mount, (b) H&E, (c) anti-cytokeratin-8,
populations and distinct vimentin-positive and cytoker-and (d) anti-smooth muscle actin staining. The arrowhead in (d)
atin-negative fibroblast-like populations (Figure 5g±i). Theindicates vascular smooth muscle cells. (e±h) Appearance of spin-
third undifferentiated tumor gave rise to lung and kidneydle-cell tumors (Sp) that form when Str1 expression is induced in
vivo or prior to injection as seen by (e) H&E, (f) Alcian blue, (g) metastases and expressed both cytokeratins and vi-
anti-vimentin, and (h) anti-cytokeratin-8 staining. Areas of cartilage mentin (Figure 5d±f). A cell line derived from the primary
(chondroid metaplasia, Cm) are present in the upper right corner
(e±h). Scale bars, (a) 200 mm and (b±h) 100 mm.
(B) Tumor incidence (percent of injected sites) and volume (cm3;
mean 6 SEM) following injection of parental (Scp2), nonexpressing maintained with or without Tet (two-tailed Fisher's exact test); ²,
(p2S3), uninduced (S10un), and preinduced (S10pre) cells into p , 0.05 versus S10un cells in mice maintained with Tet and p ,
cleared mammary fat pads in mice maintained for 6 weeks with (1) 0.001 versus S10pre cells in mice maintained with or without Tet
or without (2) Tet in their drinking water or without Tet for the first (Fisher's exact test); ³, p , 0.005 and p , 0.001 versus S10pre cells
12 days only (2/1). *, p , 0.0001 versus S10pre cells in mice in mice maintained with and without Tet, respectively (t test).
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Figure 4. Histologic Appearance of Normal and WAP-Str1 Mammary Glands
Histologic sections are from (a) nontransgenic, (b±g) WAP-Str1 transgene±expressing, (h) WAP-Str1 transgene±nonexpressing, and (i) Str1/
TIMP1 double transgene±positive female mice.
(a) Normal mammary gland with resting ducts (Du), abundant adipose tissue (asterisk), and minimal periductal (Pd) and septal (S) collagen
(stained blue).
(b) Severe hyperplasia (Hp) with considerable intervening fibrosis (Fb; stained blue) and multilocular adipocytes (asterisk).
(c) Hyperplastic alveolar nodule (HAN) with lipid droplets characteristic of secretory activity even though this gland comes from a nulliparous mouse.
(d) Multifocal alveolar hyperplasia (Hp) with eosinophilic (pink) fibrotic areas and multilocular adipocytes (asterisk).
(e) Intraductal papillary hyperplasia with lymphocytic infiltrates (Ly). The small hyperchromatic cells (Me) were cytokeratin-8 negative and
smooth muscle actin positive, indicating the abnormal presence of myoepithelial cells within the severely distended ducts.
(f) Atypical hyperplasia (AH) with lymphocytic infiltrates (Ly) and mild fibrosis (Fb).
(g) Atypical hyperplasia with considerable fibrosis.
(h and i) Normal mammary histology seen with the loss of Str1 transgene expression or its inhibition by TIMP1, respectively.
(a and b) Masson's trichrome. (c±i) Hematoxylin/eosin. Scale bar, 200 mm.
mammary tumor also coexpressed cytokeratin and vi- should quench this phenotype. Thus, we mated WAP-
mentin and formed invasive tumors that were cytokera- Str1 mice with mice carrying a human TIMP1 transgene
tin and vimentin positive in vivo (data not shown). under the control of the same WAP promoter to examine
In contrast to the Str1-expressing transgenic mice, the effect of TIMP1 on the development of mammary
nontransgenic littermate controls (median age 18 months) lesions in WAP-Str1 mice. Mammary hyperplasias were
exhibited a low incidence of mild hyperplasia, fibrosis, examined as a surrogate endpoint in 10- to 16-month-
and lymphocytic infiltration (Figure 3). These low inci- old female offspring (Figure 6). Only 3 of 16 mice (19%)
dence rates were similar for virgin and parous controls. carrying both Str1 and TIMP1 transgenes had mild mam-
We also isolated two sublines of Str1 transgenic mice mary hyperplasias, whereas 8 of 11 mice (73%) carrying
in which expression of the transgene was silenced and the Str1 transgene alone had moderate to severe hyper-
could not be detected by RT-PCR, presumably due to plasias. A similar frequency (66%) was seen in the cohort
transgene methylation as determined by altered sensi- of 100 WAP-Str1 females from the same transgenic
tivity to restriction endonucleases. The nonexpressing founder (M2-5). Mice carrying only the TIMP1 transgene
transgenic mice (median age 13 months) also showed had a slightly altered involution phenotype but were
a low incidence of mild lesions (Figure 3). These data otherwise normal. Nontransgenic littermates had en-
indicate that expression of the Str1 transgene is required tirely normal mammary glands. These data indicate that
to promote neoplastic progression. active Str1 is required for mammary lesions to develop.
TIMP1 Inhibits the Development of Mammary
Str1 Expression Promotes StereotypedHyperplasias in Str1 Transgenic Mice
Genomic ChangesIf the induction of neoplasia by Str1 is due to its proteo-
Because Str1 acts extracellularly, we wanted to deter-lytic activity, then overexpression of its endogenous in-
hibitor, tissue inhibitor of metalloproteinases-1 (TIMP1), mine if tumorigenicity was accompanied by genomic
Stromelysin-1 Promotes Mammary Carcinogenesis
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Figure 5. Histologic Appearance of Malignant Mammary Tumors from Str1 Transgenic Mice
(a±c) Moderately differentiated adenocarcinoma (Ad) with adjacent and intervening vimentin-positive stromal cells (St).
(d±f) Renal metastasis (Met) from an undifferentiated mammary carcinoma. Normal kidney (Kid) is present on the right.
(g±i) Carcinosarcoma with distinct carcinomatous (Ca) and sarcomatous (Sa) areas exhibiting epithelial and mesenchymal features, respectively.
H&E, hematoxylin/eosin stains. Scale bar, 200 mm.
reorganization. Analysis of ten mammary lesions from chromosome 15 with EMT was obtained from the p2S
cells and their tumors. DNA gains in chromosome 15three Str1 transgenic lines by comparative genomic hy-
bridization (CGH) revealed DNA losses in specific re- were seen in the preinduced p2S10 and p2S7 cells and
their tumors but not in the parental cells (Figure 7B).gions of mouse chromosomes 4 and 7 in both premalig-
nant and malignant lesions (Figure 7A). In addition, the Identical gains in the middistal portion of chromosome
15 were seen in both microdissected spindle-cell andthree tumors with EMT and a severe hyperplasia had
DNA copy number gains on chromosomes 6 and 15. cartilage-like areas of p2S10 tumors but not in adjacent
normal stroma, indicating that both areas arose fromBecause these gains were associated with EMT, we
separately analyzed the epithelial- and mesenchymal- injected rather than host cells and that the cartilage-
like areas represent a further manifestation of EMT. Thelike populations of one carcinosarcoma after laser mi-
crodissection. The chromosome 15 amplification was preinduced cells and their tumors also showed amplifi-
cations on chromosomes 3, 5, and 11. Unlike the WAP-only seen in microdissected fibroblast-like areas that
had undergone EMT, whereas other CGH changes were Str1 mammary tumors, no changes were seen on chro-
mosomes 4, 7, or 6. Thus, although we studied relativelyseen throughout the tumor. Because the DNA from the
severe hyperplasia with gains on chromosomes 6 and few samples, our data further implicate mouse chromo-
some 15 as significant for Str1-induced tumors that have15 came from an area of tissue that was not expressly
visualized and microdissected, its genomic changes undergone EMT.
may reflect those of an occult tumor with EMT. CGH
profiles for nonneoplastic tissues from the same ten Discussion
mice (data not shown) and from two histologically nor-
mal mammary glands from separate transgenic lines Stromal MMPs Alter Neoplastic Risk
An altered stromal environment appears to presage can-were invariably normal. Thus, even with this sample size
and despite using a statistic (Fisher's exact test) that cer development. In the case of WAP-Str1 transgenic
mice, stromal defects appear (Thomasset et al., 1998)ignores consistency in direction and subchromosomal
localization, the genomic changes on chromosomes 4, well before neoplastic changes are observed. In hu-
mans, cancer susceptibility is increased in certain fi-7, 6, and 15 were remarkably nonrandom (p , 0.001,
0.01, 0.05, and 0.05, respectively). brotic and chronic inflammatory conditions (Hsieh et al.,
1998; Jacobs et al., 1999). Moreover, some inheritedIndependent evidence for an association of mouse
Cell
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Figure 7. CGH Profiles
(A) Genomic changes seen in the mammary glands of 12 individual
Str1 transgenic mice. Samples 1, 3, 10, and 11 were from one
transgenic founder line; samples 4 and 8 were from another line;
and the remaining samples were from a third independent line. Ap-
proximate locations of macroscopic DNA gains (green) and losses
(red) are indicated along otherwise unaltered (yellow) chromosomes,
with black circles representing acrocentric centromeres. Sample
12, a carcinosarcoma, was microdissected and its carcinomatous
and sarcomatous regions analyzed separately. All adjacent stromal
Figure 6. Effect of a TIMP1 Transgene on Str1 Transgene±Induced and nonmammary control tissues had normal CGH profiles.
Mammary Hyperplasias as Seen by Whole-Mount Staining (B) Normalized fluorescence intensity profiles for chromosome 15
(a) 16-month-old nontransgenic control. obtained with DNA isolated from (a) parental Scp2 cells, (b) a p2S7
(b) 16-month-old WAP-Str1 transgenic mouse with multifocal alveo- cell±derived tumor, (c) preinduced p2S10 cells, (d) microdissected
lar hyperplasia (Hp). spindle-cell areas from a tumor derived from the same preinduced
(c) 12-month-old WAP-Str1-positive/WAP-TIMP1-negative mouse cells as in (c), (e) chondroid areas from the same tumor as in (d),
with diffuse alveolar hyperplasia. and (f) normal stroma adjacent to the tumor in (d) and (e). Average
(d) 12-month-old Str1/TIMP1 double transgenic mouse from the green:red fluorescence ratios (heavy lines) 6 1 standard deviation
same litter as the mouse in (c). The mammary gland in (d) was judged (thin lines) are shown for the number of metaphase chromosomes
to be within normal limits by whole-mount and hematoxylin/eosin examined (n). Dashed horizontal lines and upper and lower dotted
staining. The glands shown are from mice that had undergone a lines indicate fluorescence ratios of 1, 1.5, and 0.5, respectively.
single pregnancy and lactation at least 5 months prior to sacrifice.
LN, lymph node. Scale bar, 500 mm.
(e) Incidence of mammary hyperplasias in double and single Here we have shown that Str1 induces tumors in ani-
transgenic mice. The single transgenic mice are from the related
mals with and without an intact immune system. UsingM2-5 line. Gray and black bars indicate mild and moderate to severe
mammary epithelial cells that express Str1 in a Tet-hyperplasias, respectively. *, p , 0.02 versus littermates carrying
regulated manner, we found that Str1 converts function-the Str1 transgene alone and p , 0.0006 versus the large cohort of
M2-5 Str1 transgenics, respectively (two-tailed Fisher's exact test). ally normal mammary epithelial cells into highly infiltra-
tive mesenchymal-like tumors in vivo. In an independent
set of experiments, we demonstrated that Str1 inducescancer syndromes result from gene defects that occur
spontaneous neoplastic progression in the mammaryin stromal cells and induce stromal changes before epi-
glands of WAP-Str1 transgenic mice. Although WAP-thelial abnormalities ever appear (Jacoby et al., 1997;
Str1 and MMTV-Str1 transgenic mice show similar prolif-Howe et al., 1998). These states of stromal remodeling
erative changes in puberty (Sympson et al., 1994; Wittyand inflammation are precisely the conditions in which
et al., 1995), neoplasms have not been described inMMPs become upregulated (Mehindate et al., 1996).
MMTV-Str1 mice. This may reflect the reported quench-Thus, injury and inflammation may contribute to tumor
ing of MMTV-driven transgene expression during preg-development through MMPs that then promote the ef-
nancy, strain differences, or the long latency and lowfects of carcinogens and preexisting gene defects. Like-
incidence of tumor formation that one would expectwise, the tumor promoter activity of phorbol esters may,
to see based on our own results. In WAP-Str1 mice,in part, stem from their ability to upregulate stromal
MMP expression (Gack et al., 1994). however, neoplastic changes arose without carcinogens
Stromelysin-1 Promotes Mammary Carcinogenesis
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or preexisting mutations, were mild or absent in the How Do MMPs Foster Tumorigenicity?
MMPs are not mutagens. Therefore, they must promoteabsence of Str1 expression, and were quenched by
TIMP1 expression. Thus, Str1 can promote mammary tumor development by virtue of their ability to affect
cellular signaling (Werb, 1997). MMPs can alter cell±cellcarcinogenesis by virtue of its proteolytic activity.
Several other observations support the participation and cell±ECM interactions and release bioactive frag-
ments (Lukashev and Werb, 1998; Noe et al., 1999). Forof stromal MMPs early in cancer development. Wild-
type fibroblasts foster the growth of human breast can- example, Str1 cleaves cell surface proteins, including
E-cadherin (Lochter et al., 1997), a tumor suppressorcer cells in nude mice, yet fibroblasts lacking MMP11/
stromelysin-3 do not (Masson et al., 1998). MMP1/colla- (Christofori and Semb, 1999). MMPs also release growth
factors, angiogenic factors, and their inhibitors from thegenase-1 transgenic mice show increased sensitivity to
chemical carcinogens (D'Armiento et al., 1995), while ECM and cell surface (Patterson and Sang, 1997; Suzuki
et al., 1997) and cleave growth factor binding proteinsMMP11 null mice have a reduced sensitivity to carcino-
gens (Masson et al., 1998). In addition, lack of either (Fowlkes et al., 1994) and receptors (Levi et al., 1996).
They can induce a reactive stroma and cause recruit-MMP9/gelatinase B or Str1 slows the development of
squamous carcinomas in human papilloma virus-16 ment of other host cells (Thomasset et al., 1998), and
they generate cleavage products that may compromisetransgenic mice (L. M. Coussens, D. Hanahan, and Z. W.,
unpublished observations). Epithelial MMPs may also cellular cytotoxicity (Kataoka et al., 1999). Thus, there
are several ways in which MMPs can influence all stagescontribute to tumorigenesis. Indeed, the lack of MMP7/
matrilysin slows intestinal adenoma formation in mice of cancer progression, including initiation.
We favor the hypothesis that MMPs act to trigger thecarrying the Apcmin mutation (Wilson et al., 1997), and
its overexpression within mammary glands accelerates E-cadherin/b-catenin pathway, which can be linked to
several aspects of cancer, including EMT, invasion, andmammary tumorigenesis in mice carrying an MMTV-neu
transgene (Rudolph-Owen et al., 1998). Thus, several genomic instability (Tlsty, 1998; Noe et al., 1999). In
support of our hypothesis, the E-cadherin cleavage andMMPs may contribute to early neoplastic progression.
b-catenin redistribution seen with Str1-induced EMT are
accompanied by upregulation of cyclin D1 (M. E. Luka-EMT Is Related to Invasive and Migratory
shev and Z. W., unpublished results), a b-catenin-Behavior and MMP Expression
regulated oncogene (Tetsu and McCormick, 1999). Thus,Our results also indicate that Str1 can trigger EMT in
Str1-induced E-cadherin cleavage may trigger both nor-culture and in vivo. EMT occurs during normal embry-
mal developmental and abnormal neoplastic changes.onic development (Hay, 1995) and wound repair (Sun-
MMPs also exert comparable effects in developmentdarRaj et al., 1992) when adherent epithelia become
and cancer. It is noteworthy that Str1 stimulates ductalmigratory and invasive. Under such conditions, MMPs
proliferation and branching during puberty (Sympson etare highly expressed by adjacent mesenchymal cells
al., 1994; Witty et al., 1995) but induces apoptosis in(Chin and Werb, 1997). EMT also occurs in high-grade
anchorage-dependent secretory epithelium during preg-cancers (Birchmeier et al., 1996; Gilles and Thompson,
nancy (Alexander et al., 1996; Thomasset et al., 1998).1996). The most aggressive human breast cancers un-
These seemingly contradictory actions can be recon-dergo EMT, so they lack E-cadherin (Sommers et al.,
ciled by noting that the normal developmental fates of1994), coexpress cytokeratins and vimentin (Domagala
the target cells differ. Mammary ducts contain stem cellset al., 1990; Sommers et al., 1994), and express MMPs,
that are triggered to divide during branching morpho-such as Str1, that are otherwise confined to stromal
genesis. They also persist throughout involution, whereascells (Ahmad et al., 1998; Martorana et al., 1998). Carci-
alveolar cells do not. These effects are also consistentnosarcomas, which are among the most aggressive can-
with the process of neoplastic transformation. The nor-cers, represent a compelling example of EMT (Gilles
mal function of Str1 in inducing ductal proliferation andand Thompson, 1996). They are extremely uncommon
invasion during puberty is precisely what Str1 does toin mice (Squartini and Pingitore, 1994) and account for
transformed mammary cells. Furthermore, although theonly about 0.1% of all human breast cancers (Fisher et
induction of apoptosis in alveolar cells may defy tumori-al., 1975), yet their rate of occurrence in Str1 transgenic
genesis, it could also provide pressure for the selectionmice appears unusually high. As their name implies,
of anchorage-independent, apoptosis-resistant clonescarcinosarcomas are composed of distinct malignant
and thereby foster tumorigenicity. Taken together withcell populations that exhibit epithelial and mesenchymal
the propensity of Str1 to foster an altered stromal micro-features, respectively. Thus, it is not surprising that the
environment (Thomasset et al., 1998), Str1 has the hall-mesenchymal-like cells of carcinosarcomas express
marks of a multifactorial tumor promoter.MMP11 (Ahmad et al., 1998), which is normally confined
to adjacent stromal cells. The acquisition of mesenchy-
mal features is also consistent with the induced expres- Do MMPs Stimulate Genomic Instability?
The presence of spontaneous tumors in Str1 transgenicsion of MMP genes, including endogenous Str1, in Str1-
transfected cells that have undergone EMT (Lochter et mice indicates that Str1 promotes either the accumula-
tion of mutations or the survival of mutant cells. Byal., 1997). Altered E-cadherin and b-catenin expression
are also hallmarks of EMT (Kim et al., 1998; Sun et al., altering cellular adhesion, MMPs could conceivably alter
cell cycle checkpoint controls and promote genomic1998). Thus, the E-cadherin cleavage and b-catenin re-
distribution seen following Str1 induction (Lochter et al., instability (Tlsty, 1998). The presence of recurrent DNA
losses in both premalignant and malignant mammary1997) may have signaling implications for both EMT and
tumorigenicity (Christofori and Semb, 1999). lesions in Str1 transgenic mice and of consistent DNA
Cell
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copy number gains in undifferentiated tumors suggests Thus, our results also indicate that once Str1 effects
that these loci contain recessive- and dominant-acting alter the phenotype and genotype of mammary cells, its
genes that contribute to early and late cancer progres- activity is no longer required for tumorigenicity. Like-
sion, respectively. They also support the hypothesis that wise, cells induced to express Str1 for 6 days in culture
MMPs can produce an abnormal stromal environment continue to undergo progressive EMT despite addition
within which clones of epithelial cells containing se- of Tet and an MMP inhibitor (Lochter et al., 1997). Thus,
lected mutations may accumulate. It is intriguing that the converted cells may perpetuate further EMT by an
the WAP-Str1 tumors are histologically diverse and arise MMP-independent feedback mechanism. This ªhit-and-
late, suggesting a stochastic evolution, yet they exhibit runº action of Str1 is also in keeping with the capacity
stereotyped genomic changes, suggesting a common of MMPs to affect signaling. Thus, although MMPs are
tumorigenic pathway. Several tumors did, however, ex- expressed throughout tumor progression, and although
hibit the unifying feature of EMT together with consistent MMP inhibitors may defy invasion, other stages of pro-
DNA gains on chromosomes 6 and 15. Although c-myc gression may become resistant to anti-proteinase ther-
is located on mouse chromosome 15 (Adolph et al., apy targeting Str1. Whether this is true for other enzymes
1987), its expression failed to correlate with DNA remains to be determined.
changes (M. D. S. et al., unpublished results). Thus, other Our findings thus indicate that Str1 can promote early
relevant genes may reside at these loci. neoplastic changes, stereotyped genomic changes, and
Most of the genomic changes in the WAP-Str1 trans- late phenotypic conversions associated with aggressive
genic mice were distinct from those in other transgenic tumor behavior. They also support the hypothesis that
mammary tumor models. For example, p53-deficient an altered stromal environment can promote neoplastic
Wnt-1 transgenic mice exhibit recurrent genomic changes transformation. Elucidation of the pathways downstream
on several chromosomes, including 4, but not 6, 7, or from Str1 will be critical for defining new molecular
15 (Donehower et al., 1995). Likewise, 82% of mammary targets.
tumors in MMTV-neu transgenic mice exhibit loss of
heterozygosity on chromosome 4 (Ritland et al., 1997), Experimental Procedures
and chromosome 4 deletions were also particularly
prevalent in our own study. Thus, our results further Cell Culture
Recombinant human Str1 (0.8 mg/ml; a gift from Dr. M. Navre, Affy-implicate the middistal region of chromosome 4 as a
max Research Institute) was prepared as described previouslypotential tumor suppressor locus. Mammary tumors in
(Lochter et al., 1999) and activated by treatment with trypsin for 30SV40 T-antigen transgenic mice show consistent DNA
min at 378C, followed by addition of soybean trypsin inhibitor. Scp2
gains in the telomeric region of chomosome 6 (Liu et cells were treated every other day for 6 days with 1 mg/ml activated
al., 1998), rather than at its centromeric end as we ob- Str1 in serum-free DMEM/F12 medium containing 5 mg/ml insulin,
served in high-grade tumors of Str1 transgenic mice. 5 mg/ml transferrin, 5 ng/ml selenium, and 50 mg/ml gentamicin with
or without the hydroxamic acid metalloproteinase inhibitor GM6001Thus, our data also indicate a number of novel loci of
(10 mM; a gift from Dr. R. Galardy, Glycomed Corp.). All other culturepotential importance.
and immunocytochemistry methods were performed as previously
described (Lochter et al., 1997).Implications for Human Cancer
If MMPs function in human cancer as they do in mice,
Tumorigenicity Assay
then MMP mutations, amplifications, or polymorphisms The developing epithelial parenchyma of abdominal (#4) mammary
may be associated with tumor development. Few stud- glands was removed from weanling scid/scid mice (DeOme et al.,
ies have addressed this possibility despite the frequent 1959), and 1 3 106 Scp2 or p2S cells in serum-free medium were
injected into residual gland-free mammary fat pads or subcutane-cloning of MMPs as tumor-specific genes. Interestingly,
ously at the nape of the neck. Mice were maintained for 6 or morea polymorphism in the human MMP1 gene promoter
weeks with or without 10 mg/ml Tet in their drinking water. Inhibitionthat creates a transcription-enhancing Ets site occurs
of enzymatic activity by intraperitoneal injection of GM6001 (100more often in tumor cell lines than in the general popula-
mg/kg/day) was not pursued, due to inhibited wound repair and
tion (Rutter et al., 1998). This suggests that enhanced postsurgical morbidity that was not seen for the carrier (4% carboxy-
MMP1 transcription may contribute to cancer suscepti- methylcellulose in PBS). Tumor volumes were calculated as length 3
bility and supports the enhanced skin carcinogenesis width2/2.
seen in MMP1 transgenic mice (D'Armiento et al., 1995).
Epigenetic inactivation of the TIMP3 promoter, seen of- Transgenic Mice
CD1 mice with an autoactivating rat Str1 transgene targeted toten in human cancers (Bachman et al., 1999), could have
mammary epithelium by the murine WAP gene promoter were gener-similar implications. A functional polymorphism has also
ated as described (Sympson et al., 1994). Five independentbeen found in the Str1 promoter (Ye et al., 1996); how-
transgenic founder lines (M2-5, M2-20, M2-21, M2-25, and M1-9),
ever, its role in cancer remains unexplored. their nontransgenic littermates, and two transgenic sublines that
Our results may also have implications concerning had lost expression of the transgene (M2-5N and M2-21N) were
the therapeutic use of MMP inhibitors. Inhibition of Str1 analyzed. All mice were housed under similar conditions, and a
by overexpression of TIMP1 quenched its ability to pro- similar fraction from each group (approximately one-third) was car-
ried through pregnancy and lactation. The CA10 WAP gene promotermote neoplasia in transgenic mice, indicating that active
(Sympson et al., 1994) was also used to generate transgenic miceStr1 is required and that neoplasia can be suppressed
overexpressing a human TIMP1 transgene (Alexander et al., 1996).if its activity is inhibited early on. Thus, a compelling
These mice expressed human TIMP1 protein primarily during preg-
argument could be made for inhibiting Str1 during any nancy and lactation (data not shown). WAP-TIMP1 mice were
stage of tumor progression. However, once the neoplas- crossed with one line (M2-5) of WAP-Str1 mice to generate double
tic process was triggered in Str1-transfected cells, tu- transgenics. Half of these were carried through at least one preg-
nancy and lactation.mors could still form without continued Str1 expression.
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Histopathology L. (1992). Expression of different tenascin isoforms in normal, hyper-
plastic and neoplastic human breast tissues. Int. J. Cancer 52,Mammary whole mounts (Sympson et al., 1994) were photodocu-
688±692.mented and reprocessed for paraffin embedment. Hematoxylin/
eosin, Masson's trichrome, and Alcian blue staining were by standard Boudreau, N., Sympson, C.J., Werb, Z., and Bissell, M.J. (1995).
methods. Antigen retrieval was by brief 0.4 mg/ml proteinase K di- Suppression of ICE and apoptosis in mammary epithelial cells by
gestion for vimentin or by microwave heating in citrate buffer. Before extracellular matrix. Science 267, 891±893.
adding peroxidase (HRP)-conjugated reagents, endogenous peroxi- Chin, J.R., and Werb, Z. (1997). Matrix metalloproteinases regulate
dase activity was blocked with a methanol/H2O2 solution. Immunolo- morphogenesis, migration and remodeling of epithelium, tongue
calization was by rat anti-mouse cytokeratin-8 (a gift from Dr. R. skeletal muscle and cartilage in the mandibular arch. Development
Kemler; 1:50) and biotinylated rabbit anti-rat IgG (Vector Labora- 124, 1519±1530.
tories; 1:200), HRP-conjugated mouse anti-bovine vimentin (DAKO; Christofori, G., and Semb, H. (1999). The role of the cell-adhesion
prediluted), or biotinylated rat anti-mouse smooth muscle actin (a molecule E-cadherin as a tumour-suppressor gene. Trends Bio-
gift from Dr. L. R. Lund; 1:50). Biotinylated antibodies were detected chem. Sci. 24, 73±76.
with avidin-biotin-HRP complexes. HRP activity was visualized with
Coussens, L.M., and Werb, Z. (1996). Matrix metalloproteinases anddiaminobenzidine, and nuclei were counterstained with Meyer's he-
the development of cancer. Chem. Biol. 3, 895±904.matoxylin.
D'Armiento, J., DiColandrea, T., Dalal, S.S., Okada, Y., Huang, M.T.,
Conney, A.H., and Chada, K. (1995). Collagenase expression in
Comparative Genomic Hybridization transgenic mouse skin causes hyperkeratosis and acanthosis and
DNAs were extracted from cultured cells, frozen tissues, or paraffin increases susceptibility to tumorigenesis. Mol. Cell. Biol. 15, 5732±
blocks by standard methods or from lightly stained paraffin sections 5739.
after laser microdissection (Emmert-Buck et al., 1996). Reference DeOme, K.B., Faulkin, L.J.J., Bern, H.A., and Blair, P.E. (1959). Devel-
and test DNAs labeled with Texas red-5-dCTP and fluorescein-12- opment of mammary tumors from hyperplastic alveolar nodules
dCTP, respectively, were hybridized to normal metaphase chromo- transplanted into gland-free mammary fat pads of female C3H mice.
some spreads; chromosomes were identified by 4,6-diamino-2- Cancer Res. 19, 515±520.
phenylindole (DAPI) counterstaining; and green:red fluorescence Domagala, W., Lasota, J., Bartkowiak, J., Weber, K., and Osborn,
intensity profiles were obtained as previously described (Bain et al., M. (1990). Vimentin is preferentially expressed in human breast car-
1997). cinomas with low estrogen receptor and high Ki-67 growth fraction.
Am. J. Pathol. 136, 219±227.
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